Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 10 selected

Guidance programme

Showing 101 to 150 of 746

TitleReference numberPublishedLast updated
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist careDG48
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerIPG763
Transperineal biopsy for diagnosing prostate cancerDG54
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcersDG52
MRI fusion biopsy systems for diagnosing prostate cancerDG53
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuriesIPG762
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoeaIPG760
Endoscopic ultrasound-guided biliary drainage for biliary obstructionIPG761
AposHealth for knee osteoarthritisMTG76
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastasesIPG759
Percutaneous thoracic duct embolisation for persistent chyle leakIPG755
Focal therapy using high-intensity focused ultrasound for localised prostate cancerIPG756
Maximal cytoreductive surgery for advanced ovarian cancerIPG757
Radiofrequency ablation for palliation of painful spinal metastasesIPG758
UrgoStart for treating diabetic foot ulcers and leg ulcersMTG42
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Endoluminal gastroplication for gastro-oesophageal reflux diseaseIPG753
Percutaneous transluminal renal sympathetic denervation for resistant hypertensionIPG754
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865

Results per page

  1. 10
  2. 25
  3. 50
  4. All